Literature DB >> 34756179

The course of action for effective anti-cytokine treatment in COVID-19.

Giulio Cavalli1, Lorenzo Dagna2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34756179      PMCID： PMC8555968          DOI： 10.1016/S2213-2600(21)00405-7

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  10 in total

Review 1.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.

Authors:  Alberto Mantovani; Charles A Dinarello; Martina Molgora; Cecilia Garlanda
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

2.  Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.

Authors: 
Journal:  Lancet Respir Med       Date:  2021-01-22       Impact factor: 30.700

3.  Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.

Authors:  Giulio Cavalli; Alessandro Larcher; Alessandro Tomelleri; Corrado Campochiaro; Emanuel Della-Torre; Giacomo De Luca; Nicola Farina; Nicola Boffini; Annalisa Ruggeri; Andrea Poli; Paolo Scarpellini; Patrizia Rovere-Querini; Moreno Tresoldi; Andrea Salonia; Francesco Montorsi; Giovanni Landoni; Antonella Castagna; Fabio Ciceri; Alberto Zangrillo; Lorenzo Dagna
Journal:  Lancet Rheumatol       Date:  2021-02-03

4.  The right place for IL-1 inhibition in COVID-19.

Authors:  Giulio Cavalli; Lorenzo Dagna
Journal:  Lancet Respir Med       Date:  2021-01-22       Impact factor: 30.700

5.  Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.

Authors:  Jozefien Declercq; Karel F A Van Damme; Elisabeth De Leeuw; Bastiaan Maes; Cedric Bosteels; Simon J Tavernier; Stefanie De Buyser; Roos Colman; Maya Hites; Gil Verschelden; Tom Fivez; Filip Moerman; Ingel K Demedts; Nicolas Dauby; Nicolas De Schryver; Elke Govaerts; Stefaan J Vandecasteele; Johan Van Laethem; Sebastien Anguille; Jeroen van der Hilst; Benoit Misset; Hans Slabbynck; Xavier Wittebole; Fabienne Liénart; Catherine Legrand; Marc Buyse; Dieter Stevens; Fre Bauters; Leen J M Seys; Helena Aegerter; Ursula Smole; Victor Bosteels; Levi Hoste; Leslie Naesens; Filomeen Haerynck; Linos Vandekerckhove; Pieter Depuydt; Eva van Braeckel; Sylvie Rottey; Isabelle Peene; Catherine Van Der Straeten; Frank Hulstaert; Bart N Lambrecht
Journal:  Lancet Respir Med       Date:  2021-10-29       Impact factor: 30.700

6.  Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis.

Authors:  Evdoxia Kyriazopoulou; Thomas Huet; Giulio Cavalli; Andrea Gori; Miltiades Kyprianou; Peter Pickkers; Jesper Eugen-Olsen; Mario Clerici; Francisco Veas; Gilles Chatellier; Gilles Kaplanski; Mihai G Netea; Emanuele Pontali; Marco Gattorno; Raphael Cauchois; Emma Kooistra; Matthijs Kox; Alessandra Bandera; Hélène Beaussier; Davide Mangioni; Lorenzo Dagna; Jos W M van der Meer; Evangelos J Giamarellos-Bourboulis; Gilles Hayem
Journal:  Lancet Rheumatol       Date:  2021-08-09

7.  Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.

Authors:  Manu Shankar-Hari; Claire L Vale; Peter J Godolphin; David Fisher; Julian P T Higgins; Francesca Spiga; Jelena Savovic; Jayne Tierney; Gabriel Baron; Julie S Benbenishty; Lindsay R Berry; Niklas Broman; Alexandre Biasi Cavalcanti; Roos Colman; Stefanie L De Buyser; Lennie P G Derde; Pere Domingo; Sharifah Faridah Omar; Ana Fernandez-Cruz; Thijs Feuth; Felipe Garcia; Rosario Garcia-Vicuna; Isidoro Gonzalez-Alvaro; Anthony C Gordon; Richard Haynes; Olivier Hermine; Peter W Horby; Nora K Horick; Kuldeep Kumar; Bart N Lambrecht; Martin J Landray; Lorna Leal; David J Lederer; Elizabeth Lorenzi; Xavier Mariette; Nicolas Merchante; Nor Arisah Misnan; Shalini V Mohan; Michael C Nivens; Jarmo Oksi; Jose A Perez-Molina; Reuven Pizov; Raphael Porcher; Simone Postma; Reena Rajasuriar; Athimalaipet V Ramanan; Philippe Ravaud; Pankti D Reid; Abraham Rutgers; Aranzazu Sancho-Lopez; Todd B Seto; Sumathi Sivapalasingam; Arvinder Singh Soin; Natalie Staplin; John H Stone; Garth W Strohbehn; Jonas Sunden-Cullberg; Julian Torre-Cisneros; Larry W Tsai; Hubert van Hoogstraten; Tom van Meerten; Viviane Cordeiro Veiga; Peter E Westerweel; Srinivas Murthy; Janet V Diaz; John C Marshall; Jonathan A C Sterne
Journal:  JAMA       Date:  2021-08-10       Impact factor: 56.272

8.  Design, analysis and presentation of factorial randomised controlled trials.

Authors:  Alan A Montgomery; Tim J Peters; Paul Little
Journal:  BMC Med Res Methodol       Date:  2003-11-24       Impact factor: 4.615

9.  Dexamethasone in Hospitalized Patients with Covid-19.

Authors:  Peter Horby; Wei Shen Lim; Jonathan R Emberson; Marion Mafham; Jennifer L Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray
Journal:  N Engl J Med       Date:  2020-07-17       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.